

(b) a physiologically acceptable carrier or excipient;
and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

37. (Amended) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1 or a variant thereof from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with WT1-specific T cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and

(b) a non-specific immune response enhancer;
and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

63. (Amended) A method for stimulating and/or expanding T cells, comprising contacting T cells with a WT1 polypeptide, a polynucleotide encoding a WT1 polypeptide and/or an antigen presenting cell that expresses a WT1 polypeptide, wherein said WT1 polypeptide consists of an immunogenic portion of native WT1, or a variant thereof that differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with WT1-specific T cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144, under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

65. (Amended) A method according to claim 64, wherein the bone marrow, peripheral blood or fraction is obtained from a patient afflicted with a malignant disease associated with WT1 expression.

66. (Amended) A method according to claim 64, wherein the bone marrow, peripheral blood or fraction is obtained from a mammal that is not afflicted with a malignant disease associated with WT1 expression.

68. (Amended) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising:

- (a) one or more of:
 - (i) a WT1 polypeptide;
 - (ii) a polynucleotide encoding a WT1 polypeptide; or
 - (iii) an antigen-presenting cell that expresses a WT1 polypeptide;

wherein said WT1 polypeptide consists of an immunogenic portion of native WT1, or a variant thereof that differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with WT1-specific T cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and

- (b) a physiologically acceptable carrier or excipient;
- and thereby stimulating and/or expanding T cells in a mammal.

69. (Amended) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising:

- (a) one or more of:
 - (i) a WT1 polypeptide;
 - (ii) a polynucleotide encoding a WT1 polypeptide; or
 - (iii) an antigen-presenting cell that expresses a WT1 polypeptide;

wherein said WT1 polypeptide consists of an immunogenic portion of native WT1, or a variant thereof that differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with WT1-specific T cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and